Standout Papers

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorec... 2004 2026 2011 2018 3.8k
  1. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer (2004)
    David Cunningham, Yves Humblet et al. New England Journal of Medicine
  2. Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer (2004)
    E O’Brien, Nely Wigler et al. Annals of Oncology
  3. Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (2006)
    Ghassan K. Abou‐Alfa, Lawrence H. Schwartz et al. Journal of Clinical Oncology
  4. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial (2012)
    Jordi Bruix, Jean‐Luc Raoul et al. Journal of Hepatology
  5. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial (2018)
    Philippe Armand, Andreas Engert et al. Journal of Clinical Oncology
  6. Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib (2014)
    Andrew X. Zhu, Masatoshi Kudo et al. JAMA
  7. SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma (2014)
    Andrew X. Zhu, Olivier Rosmorduc et al. Journal of Clinical Oncology
  8. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial (2017)
    Evan Alley, Juanita Lopez et al. The Lancet Oncology
  9. Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors (2021)
    Giuseppe Curigliano, Hans Gelderblom et al. Clinical Cancer Research
  10. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis (2021)
    Masatoshi Kudo, Ana Matilla et al. Journal of Hepatology
  11. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW. (2024)
    Peter R. Galle, Thomas Decaens et al. Journal of Clinical Oncology

Immediate Impact

5 by Nobel laureates 6 from Science/Nature 153 standout
Sub-graph 1 of 17

Citing Papers

Immune checkpoint therapy—current perspectives and future directions
2023 StandoutNobel
Hepatocellular carcinoma
2022 Standout
25 intermediate papers

Works of Armando Santoro being referenced

CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis
2021 Standout
Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial
2016
and 25 more

Author Peers

Author Last Decade Papers Cites
Armando Santoro 17399 13437 8609 903 33.7k
John D. Hainsworth 21144 12105 6869 623 36.4k
Salvatore Siena 26080 11832 8267 531 36.7k
Heinz‐Josef Lenz 23991 9031 7979 856 34.9k
Josep Tabernero 33324 14187 9222 1.1k 49.1k
Leonard B. Saltz 27418 9385 5864 533 37.4k
Scott Kopetz 19936 6578 7393 661 28.1k
Yoon‐Koo Kang 11984 13225 3769 543 25.4k
Fortunato Ciardiello 21501 11605 4479 626 33.5k
Filippo de Braud 17473 8522 3280 749 26.0k
Bengt Glimelius 29523 9594 6028 690 40.5k

All Works

Loading papers...

Rankless by CCL
2026